During the past decade, Bon Secours Richmond conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Bon Secours Richmond" are "Cervical Cancer" (1 trials), "Chronic Liver Disease" (1 trials), "Colorectal Cancer" (1 trials), "Gastric Cancer" (1 trials) and "Head and Neck Squamous Cell Carcinoma" (1 trials). Many other conditions were trialed in "Bon Secours Richmond" in a lesser frequency.

Most popular intervention types in "Bon Secours Richmond" are "Drug" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "N-803 + Pembrolizumab" (2 trials), "Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab" (1 trials), "Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed" (1 trials), "HepQuant SHUNT Liver Diagnostic Test" (1 trials) and "N-803 + Atezolizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Bon Secours Richmond" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Bon Secours Richmond". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Bon Secours Richmond, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Bon Secours Richmond, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".